Valneva SE (EPA:VLA)

Market Cap	746.34M
Revenue (ttm)	196.33M
Net Income (ttm)	-67.04M
Shares Out	171.73M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	324,385
Average Volume	1,142,899
Open	4.300
Previous Close	4.346
Day's Range	4.166 - 4.300
52-Week Range	1.730 - 5.420
Beta	1.14
RSI	43.78
Earnings Date	Nov 20, 2025

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 713
• Stock Exchange: Euronext Paris
• Ticker Symbol: VLA

Financial Performance

In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.